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Monitoring Response to Therapy
Mike M. Sathekge, MD, PHD,* Alfred O. Ankrah, MD,*,† Ismaheel Lawal, MD,* and
Mariza Vorster, MD, PHD*
Monitoring response to treatment is a key element in the management of infectious diseases,
yet controversies still persist on reliable biomarkers for noninvasive response evaluation. Con-
sidering the limitations of invasiveness of most diagnostic procedures and the issue of expression
heterogeneity of pathology, molecular imaging is better able to assay in vivo biologic processes
noninvasively and quantitatively. The usefulness of 18F-FDG-PET/CT in assessing treatment re-
sponse in infectious diseases is more promising than for conventional imaging. However, there
are currently no clinical criteria or recommended imaging modalities to objectively evaluate the
effectiveness of antimicrobial treatment. Therapeutic effectiveness is currently gauged by the pa-
tient’s subjective clinical response. In this review, we present the current studies for monitoring
treatment response, with a focus on Mycobacterium tuberculosis, as it remains a major world-
wide cause of morbidity andmortality. The role of molecular imaging in monitoring other infections
including spondylodiscitis, infected prosthetic vascular grafts, invasive fungal infections, and a
parasitic disease is highlighted. The role of functional imaging in monitoring lipodystrophy asso-
ciated with highly active antiretroviral therapy for human immunodeficiency virus is considered.
Wealso discuss the key challenges and emerging data in optimizing noninvasive response evaluation.
Semin Nucl Med 48:166–181 © 2017 Elsevier Inc. All rights reserved.
Introduction
Despite new antimicrobial drugs licensed in recent years,infection remains among the leading causes of death,
taking the life of 10-15 million people every year.1 This is
further exacerbated by the syndesmosis of human immuno-
deficiency virus (HIV) and tuberculosis (TB), leading to the
majority of fatal cases occurring in the developing world.2
Even in developed countries, treatment of patients with in-
fections is becoming increasingly difficult because of rising
rates of antimicrobial drug resistance. The evolution of an-
timicrobial resistance is exacerbated by the overuse and
inappropriate use of antimicrobials, and complicated by the
evolutionary capacity of infectious pathogens to adapt to new
ecological niches created by human endeavor.1 Complicat-
ing matters is the unpredictability of infectious diseases in
general and their potential for explosive global effect, as ex-
emplified by the current pandemics of HIV and TB. Hence,
this back-and-forth struggle between human ingenuity and
microbial adaptation is a perpetual challenge.3-5 As such, our
response to these challenges must also be perpetual and able
to circumvent the adaptations of these microbial agents. Chief
among a number of approaches to meet this ever-present chal-
lenge is to optimize monitoring of response to therapy.
Biomarkers for Monitoring
Response to Therapy
The World Health Organization defines a biomarker as an ob-
jectively measured characteristic used as an indicator of a
normal or pathologic biologic process or a pharmacologic re-
sponse. As such, an ideal biomarker for infection must possess
diagnostic, prognostic, and follow-up therapy characteristics.6
Furthermore, biomarkers should be both sensitive and spe-
cific, measurable with good precision and reproducibility,
readily available, affordable, responsive to minor changes, and
provide timely results.7 However, in clinical practice, there
is a considerable overlap of biomarker values between dif-
ferent infectious (bacterial, viral, parasitic) and noninfectious
etiologies. These limitations have been demonstrated on both
commonly used biomarkers such as procalcitonin (PCT),
C-reactive protein (CRP), white blood cell, or neutrophil count,
and the still experimental and not commercially available
biomarkers such as soluble urokinase-type plasminogen
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activator receptor, soluble triggering receptor expressed on
myeloid cells, and macrophage inhibitory factor.8 Some of the
reasons why these biomarkers cannot be expected to become
isolated “magic bullets” are the relevant causes of false-
positive and false-negative results of these biomarkers. For
instance, the CRP response is blunted in fulminant hepatic
failure, but overall the clinical relevance of renal dysfunc-
tion, chronic liver insufficiency, and corticosteroid treatment
on PCT and CRP seems to be negligible.9 PCT levels in the
absence of bacterial infections are higher in patients with
chronic kidney disease than in those without, and levels de-
crease after renal replacement therapy with either transplant
renal graft or hemodialysis. The magnitude of these differ-
ences in PCT levels depends on the method used to assay
the biomarker.10 Microbiological markers such as blood cul-
tures and PCR methods still have relatively low sensitivity and
lack accurate prognostic rules. Thus, there is an ongoing unmet
need for biomarkers that can reliably distinguish between
responders and nonresponders and help to optimize antimi-
crobial treatment decisions. The consequences of this unmet
need include an increase in multiresistant pathogens, high
costs for inpatient care, and potential adverse outcomes. Hence,
available evidence needs to be better incorporated into clini-
cal decision-making, including imaging.
Imaging as a Biomarker for
Monitoring Response to Therapy
Given the complexities of the infection response, no 1
biomarker will be sufficient to diagnose and monitor infec-
tion. Combinations of biomarkers are needed, and molecular
imaging is gaining prominence in this regard.
MRI and conventional nuclear medicine tests can be em-
ployed to assess response to therapy. However, these
approaches may become accurate only months after com-
plete eradication of the infection and therefore cannot be used
to provide an early assessment of therapeutic efficacy.11 As a
result of the limitation of these imaging modalities coupled
with the expression heterogeneity by pathology, molecular
imaging with PET/CT is better able to assay in vivo biologic
processes noninvasively and quantitatively. Molecular imaging
has been a particularly attractive tool for monitoring treat-
ment in clinical cancer practice. The radiotracer 18F-FDG is
widely used in clinical medicine for noninvasive imaging,
staging, and monitoring treatment responses of neoplastic
diseases.12,13 18F-FDG has also been used to image infection
and inflammation, because detection is proportional to the
glycolytic activity of the cells that trap it.14-16
The accumulation of 18F-FDG in inflammatory and infec-
tious diseases is based on the high uptake in activated
leukocytes, which use glucose as an energy source only after
activation during the metabolic burst. Transport of 18F-FDG
across the cellular membrane is mediated by the glucose trans-
porter proteins, which have increased expression on the cell
membrane of inflammatory cells.17,18 Rabkin et al showed that
although hyperglycemia led to a higher false-negative rate in
patients with cancer it had, in contrast, no significant effect
on the detectability rate of infectious foci.19 There is currently
a lack of approved guidelines for monitoring response with
18F-FDG-PET/CT; however, rapidly growing data appear to
show 18F-FDG-PET/CT is valuable for therapy monitoring in
some infectious and inflammatory diseases. The data indi-
cate that 18F-FDG-PET/CT could even play a pivotal role in
the management of infections, leading to better drug dosage,
confirm the usefulness of the treatment, and early modifica-
tion of the therapeutic strategy. Moreover, recent interesting
findings by Kagna et al20 demonstrate that antibiotic treat-
ment appears to have no clinically significant impact on the
diagnostic accuracy of 18F-FDG-PET/CT performed for the as-
sessment of known or suspected infectious processes, despite
the long duration of appropriate antimicrobial treatment. This
means that in spite of the appropriateness of the adminis-
tered antibiotics, if there is poor, delayed, or lack of response,
18F-FDG-PET will remain positive. Importantly, Kagna et al20
recommended that further prospective well-designed studies
are needed to determine whether serial maximum standard-
ized uptake value (SUVmax) 18F-FDG measurements will
indeed be able to demonstrate therapy control and define re-
sponse to antibiotics in various infectious processes.
Quantifying Response
Determining an accurate and repeatable means of evaluat-
ing response to therapy remains a challenge in patients with
infection. An objective assessment of response of the primary
site of infection and any metastatic foci is necessary to measure
therapeutic effect. One such method makes use of SUVmax.21
Some problems associated with quantifying response in in-
fection include:
• In clinical practice, a baseline study is unlikely to have been
done
• Limited data and poor correlation between serum
biomarkers and imaging biomarkers
• SUV cutoff value (threshold) not established
• Delta SUVmax between 2 studies (baseline and follow-
up) not established
• Time point during the course of treatment when the follow-
up scan must be done
• Definition of the region of interest is more difficult than
with solid tumors
• No clear guidelines on interpretation of mixed response
(especially in TB)
• General and technical issues of quantification of SUV
Most studies have focused on changes in SUV between base-
line and follow-up scans. Treatment response is considered
as decrease in SUVmax between the baseline and the follow-
up studies. In a study of 38 patients with spondylodiscitis,
the delta-SUVmax had a higher sensitivity for early identifi-
cation of responders than CRP levels.22 In another study, the
response to antibiotic treatment was defined by a signifi-
cant reduction in SUVmax between baseline and post-
treatment PET/CT studies in 15 patients with infectious
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discitis.23 18F-FDG-PET/CT was also a useful tool in monitoring
therapy results in 25 patients with prosthetic vascular graft
infections, defining partial response as a decrease in SUVmax
of more than 20%.24 On the contrary, Riccio et al found quan-
tification of activity could not reliably differentiate patients
with active infection from those without active infection and
those who had had a successful response to therapy. They
rather relied on the pattern of activity as critical to accurate
interpretation.21
TB and Monitoring of Response to
Therapy
Perhaps we need to ask several questions with regard to TB:
(1) What is the role of PET/CT, and does it improve outcome?
(2) For which patients or groups of patients should PET/
CT be used?
(3) What is the optimal duration of therapy?
(4) What is the role of biomarkers (eg, CRP or PCT) in de-
termining duration of therapy and their correlation with
18F-FDG-PET/CT?
Although great progress has been made with relatively ef-
fective chemotherapy for TB, the host-pathogen interaction
is incompletely understood. Therefore, treatment of TB in-
volves administration of multiple drugs with the recommended
regimen for drug-sensitive TB (isoniazid and rifampicin for
6 months, together with pyrazinamide and ethambutol for
the first 2 months) being highly effective. Unfortunately, this
regimen’s main drawback is the duration of therapy. This is
supported by the proportion of patients defaulting therapy
increased linearly after 4 weeks and varied between 7% and
53.6% in a systematic review.25 One key explanation for this
long duration of treatment is based on the findings that during
the first 2 months of effective therapy, viable bacteria in sputum
samples from patients show a characteristic biphasic kill curve
(Fig. 1).26,27 This indicates that there are at least 2 bacterial
subpopulations that differ in their intrinsic drug susceptibility:
1 subpopulation is rapidly killed, and the other responds more
slowly. The bacilli in this second and slowly replicating or
nonreplicating subpopulation have been classified as persistent.
The effectiveness of combination TB chemotherapy regi-
mens has been theorized to be the result of the differential
effectiveness of the individual agents against these discrete
bacterial subpopulations.11 However, there are still unex-
plained observations in the sense that after the first 2 months
of therapy, most patients no longer have bacilli in their sputum
that can be cultured, but many must still complete an addi-
tional 4 months of treatment to avoid relapse.
Thus, the 6-month standard course of therapy for drug-
susceptible disease is clearly longer than is necessary for some
patients.28-31 Unfortunately, it has proven extremely challeng-
ing to identify which patients can be successfully treated for
a shorter time. A clinical trial of shorter treatment for patients
without cavities on baseline chest films and with negative
sputum cultures at 2 months was unsuccessful.32 This high-
lights the need for a combination of biomarkers that includes
molecular imaging to optimize treatment duration, taking into
consideration that we should avoidmultidrug resistance (MDR)
TB. The recommended MDR TB regimen is toxic, poorly tol-
erated and prolonged (up to 24months), and not based on data
from controlled trials. Treatment success rates inmany countries
are only around 50%, needless to mention about the emer-
gence of incurable TB (failures and resistance beyond XDR
TB), totally drug-resistant TB, to which there is no solution.33,34
The lack of reliable surrogate markers of drug efficacy
hampers efforts to develop new drugs, shorten the treat-
ment time, and reduce extensively drug-resistance (XDR) TB
the disease burden. The events that occur in the lungs and
other tissues to eliminate Mycobacterium tuberculosis during
drug treatment are poorly understood, especially at the lesional
level. There is evidence that specific lesion types, particu-
larly cavities, are associated with poor treatment outcomes,35,36
but for the many pathologies present in patients with TB, we
currently have little understanding of the kinetics of resolu-
tion by different drugs.37,38 Assessing which lesions respond
most slowly and optimizing regimens to resolve them offer
a rational route forward to shortening the duration of treat-
ment; this is the ultimate goal for ongoing research with
molecular imaging. Currently, response to anti-TB treat-
ment in patients with bacillus-positive TB is monitored
principally by serial bacteriologic examinations, whereas re-
sponses in patients with bacillus-negative TB, including smear-
negative pulmonary and most cases of extrapulmonary TB,
are usually monitored clinically or radiographically. Patients
with noncavitary tuberculomas usually have no symptoms,
and their cultures are usually negative. After 3 and 12 months
of treatment for pulmonary tuberculomas, however, only 40%
and 76%, respectively, of tuberculomas decreased in size.36,39
18F-FDG-PET/CT as a Biomarker
for Monitoring Infection
Based on the findings of several investigators (Tables 1 and
3), PET/CT technology could be used in clinical trials of
Figure 1 Graph showing the effect of anti-TB therapy on subpopu-
lations of Mycobacterium tuberculosis present in sputum over time.
Adapted from Horsburgh et al26 with kind permission of the authors.
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investigational drugs or diagnostics to predict the efficacy of
a treatment regimen early on, potentially shortening the du-
ration of a trial and saving resources.
Metabolic activity as studied on 18F-FDG-PET/CT can be
taken as a reliable marker for serial quantification of activity
in infectious disease process like TB or invasive fungal in-
fection (IFI). The changes in glycolytic activity within the
inflammatory lesion as measured by 18F-FDG uptake corre-
lates well with the clinical markers of response and possibly
provide more objective evidence of response rather than the
nonspecific biochemical markers such as erythrocyte sedi-
mentation rate. This may translate into a potential clinical role
for 18F-FDG as an imaging biomarker for noninvasive re-
sponse evaluation infection and for guiding modulation of
therapy.
18F-FDG-PET or PET/CT for
Monitoring Response in TB
Early work with 18F-FDG-PET showed different time activ-
ity curves for FDG uptake in acute, healing, and chronic lesions
caused by different infective etiologies including TB.40 This
suggested a role for monitoring therapy of anti-TB chemo-
therapy with 18F-FDG-PET that was explored by different
authors in evaluating response to anti-TB chemotherapy in
both pulmonary and extrapulmonary TB (Table 1).
Preclinical Assessment of
Response to TB Therapy With
18F-FDG-PET/CT
In TB, the usefulness of 18F-FDG-PET and PET/CT has been
explored in the preclinical setting in various animal models.
MouseModel
Metabolic activity in the lungs of mice with TB on
18F-FDG-PET was found to correlate with the bactericidal ac-
tivity of anti-TB chemotherapy in BALB/c and C3HeB/FeJ mice
in 1 study.61 Mice strains such as BALB/c show little evi-
dence of necrosis and do not reflect human disease accurately.
The C3HeB/FeJ on the other hand form necrotic lesions after
infection with M tuberculosis and develop heterogeneous pul-
monary lesions reflecting human pulmonary TB more closely.45
The C3HeB/FeJ model has been used in combination with
18F-FDG-PET/CT to test new anti-TB drugs.61,64 In 1 study,
18F-FDG-PET/CT was evaluated in C3HeB/FeJ mice that were
infected with TB and subsequently treated.64 This study dem-
onstrated that 18F-FDG-PET/CT was able to accurately follow
the evolution of TB granulomas over time. 18F-FDG-PET de-
tected new TB lesions over the time course over which mice
were studied, suggesting that dormant Mycobacterium bacilli
may reside outside TB lesions and may explain the differen-
tial response with the development of new TB lesions in
previously uninvolved sites while on treatment. 18F-FDG-PET
in mice can potentially help explain TB pathogenesis and
complex human response treatment. Evaluation of anti-TB
therapy in mice for instance, pyrazinamide and clofazimine
demonstrated only moderate bacterial killing in C3HeB/FeJ
mice but were highly effective in BALB/c mice without ne-
crotic lesions in necropsy studies.65,66 18F-18 FDG-PET studies
in mice present a useful tool in investigating therapeutic
efficacy.45
Rabbit Model
A study using rabbits determined that changes in metabolic
uptake in the lungs of rabbits with TB could be observed as
early as 1 week after starting anti-TB therapy.52 Metabolic
changes preceded morphologic changes. The rabbit model
of TB reflects different aspects of human disease including
fibrotic granuloma with caseous necrosis foci that harbor small
persisting mycobacterial subpopulations that have adapted
to the harsh microenvironment.45 The different disease states
and disease progression that can be induced in rabbits allow
monitoring of anti-TB drugs at the lesional level with
18F-FDG-PET/CT.45,67
Nonhuman Primates
A reduction in 18F-FDG avidity in the lung of cynomolgus
macaques with active TB on anti-TB treatment correlated with
reduced bacterial load at necropsy of these animals.51 In this
study, changes in SUV from baseline to end of treatment of
about 8-12 weeks were compared for isoniazid and rifam-
picin monotherapy. Isoniazid-treated animals demonstrated
a transient increase in metabolic activity of TB lesions, whereas
there was a net decrease in rifampicin-treated animals. Animals
treated with the 4 standard first-line TB drugs showed greater
metabolic reduction than those treated with individual drugs.
The study suggests 18F-FDG-PET/CT may provide an early
correlate that can be used to test novel combination of drugs
before translating drug combinations into humans. In another
study, 18F-FDG-PET/CT findings early in the course of anti-
TB therapy predicted the outcome of treatment in nonhuman
primates.47 These findings were translated to humans, and
18F-FDG-PET/CT was used in monitoring multidrug resis-
tant patients.46
Clinical Assessment of Response
to TB With 18F-FDG-PET/CT
In clinical studies, several authors demonstrated the ability
of 18F-FDG-PET or PET/CT to monitor response of TB in pul-
monary and extrapulmonary sites.42,43,62 Table 1 summarizes
the findings that have been reported. Figure 2 shows a patient
who had serial 18F-FDG-PET/CT scans to monitor therapy.
Some authors reported the changes of FDG being apparent
in some sites as early as 3 days although most authors re-
ported on changes after 1 month or longer.54,59
Pulmonary TB
In pulmonary TB, 18F-FDG provided a noninvasive method
of following up TB lesions. This enabled real-time assessment
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Table 1 Original Articles of 18F-FDG-PET or PET/CT in Monitoring Response in TB
Author Journal Type of Study and Subjects Comment or Conclusion
Lefebvre et al41 Nucl Med Biol 2017 Clinical—patients with TB
lymphadenitis
SUVmax follow-up is a potential tool for
monitoring response
Stelzmueller et al42 Clin Nucl Med 2016 Clinical—pulmonary and EPTB May be useful for the establishment of
individual treatment regimens
Arbind et al43 Indian J Nucl Med 2016 Clinical—EPTB PET/CT is a powerful tool in monitoring
therapy in TB
Malherbe et al69 Nat Med 2016 Clinical—HIV-negative patients Patients with durable clinical cure may have
metabolic uptake, which may persist in
the post-therapeutic period
Maruwski et al64 J Nucl Med 2014 Preclinical—C3HeB/FeJ mice Suggested dormant Mycobacterium
tuberculosis bacilli were present outside
TB lesions in normal lung tissue
Chen et al46 Sci Transl Med 2014 Clinical—MDR TB patients Quantitative changes in SUV at 2 months
were associated with long-term outcomes
Coleman et al47 Sci Transl Med 2014 Clinical and preclinical—MDR
TB patient and cynomolgus
macaques
TB treatment was associated with reduction
in FDG activity in the lung
Santhosh et al48 Indian J Nucl Med 2014 Clinical—Pancreatic
tuberculosis
Noninvasively evaluated therapeutic
response in peripancreatic TB
Ghesani et al49 Am J Respir Crit Care Med
2014
Clinical—latent TB (LTBI) Monitored response in patient treated for
LTBI
Dureja et al50 Eur Spine J 2014 Clinical—Extrapulmonary
(vertebral) TB
SUVmax was found to be a quantitative
marker of response to therapy




Efficacy of a single anti-TB or multidrug
regime could be identified within 1 or 2
months of treatment
Via et al52 Antimicrob Agents Chemother
2012
Preclinical—rabbits Significant reduction in FDG avidity of TB
lesions seen as early as 1 week, whereas
CT features (size and density) changed
more slowly with anti-TB therapy
Martinez et al53 Int J Tuberc Lung Dis 2012 Clinical—EPTB Allows early evaluation of anti-TB therapy
especially in EPTB
Yadla et al54 Indian J Nucl Med 2012 Clinical—EPTB Useful in early assessment of anti-TB
therapy suggested response in some sites
of TB as early as 3 days
Park et al55 Nucl MedMol Imaging 2012 Clinical—EPTB Useful for estimating patient’s therapeutic
response to anti-TB
Sathekge et al56 EJNMMI 2012 Clinical—Lymph nodes of
TB-HIV coinfected patients
evaluated at 4 months
Useful in discriminating responders to anti-
TB therapy from nonresponders by the
metabolic uptake in the lymph nodes
Sathekge et al57 J Nucl Med 2011 Clinical—TB burden at before
therapy in TB-HIV coinfected
patients evaluated
Useful in predicting patients likely to fail
treatment after 4 months (prognosis)
Tian et al58 Acta Radiol 2010 Clinical—EPTB Useful in monitoring response in EPTB
Harisankar et al59 J Postgraguate Med 2010 Clinical—EPTB Demonstrated response to anti-TB therapy
as early as 8 weeks
Demura et al60 EJNMMI 2009 Clinical—pulmonary
mycobacteriosis
Useful in monitoring response to both TB
and nontuberculous myocobateria




Correctly identified bactericidal activity of
anti-TB therapy
Park et al62 Clin Nuc Med 2008 Clinical—pulmonary
tuberculomas
Useful for monitoring response in
tuberculoma
Hofmeyr et al63 Tuberculosis (Edin) 2007 Clinical—EPTB Useful to monitor therapy and may guide
duration of treatment
Ichiya et al40 Ann Nucl Med 1996 Clinical—TB and other
infections such as fungal and
bacterial
Identified patterns for time activity curves of
FDG uptake suggesting a role in
monitoring therapy
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of pulmonary TB lesions over time. In 1 study, 47 patients
with pulmonary mycobacteriosis were evaluated.
18F-FDG-PET/CT was used to monitor treatment in 14 of these
patients. All 14 patients showed a decrease in metabolic uptake
during treatment, demonstrating the usefulness of FDG-PET/
CT in monitoring therapy of pulmonary TB andMycobacterium
avium-intracellulare complex.60 Other studies have demon-
strated 18F-FDG-PET/CT is useful for monitoring pulmonary
TB and may be useful for establishing individual treatment
regimens.42,43 Figure 3 shows 18F-FDG-PET/CT used to monitor
therapy in a 21-year-old woman with pulmonary TB. The
18F-FDG-PET/CT scan during anti-TB therapy at 2 months
demonstrates decrease in size and metabolic activity com-
pared with baseline, indicating that patient is most likely going
to respond to her current drug regimen. Figure 4 demon-
strates the use of 18F-FDG-PET/CT to monitor therapy in a
20-year-old female with TB-HIV coinfection at baseline, at
2 months of therapy, and at the end of therapy at 6 months.
There is independent response of TB lesions to anti-TB che-
motherapy with improvement of the pulmonary lesions but
development of new abdominal TB lymphadenitis on the sub-
sequent (2-month follow-up) study. This is consistent with
the concept that different TB lesions respond or progress dif-
ferently within the same patient.45
Extrapulmonary TB
In extrapulmonary TB, several studies have demonstrated the
use of 18F-FDG-PET/CT in monitoring therapy at various
sites.41,48,50 The role of 18F-FDG-PET/CT in these sites is par-
ticularly important, as there may be no pulmonary disease
component, thus precluding the use of monitoring disease
with serial bacteriologic sputum assessment. Again, the site
of the disease may be unsuitable for repeated biopsy such as
in the skeleton50 or the pancreas,48 where the risk of com-
plications from repeated biopsies is high and morbidity is
severe if complications develop. The duration of treatment
for extrapulmonary disease is variable, and monitoring with
18F-FDG-PET/CT may help in determining the appropriate
time to stop therapy.63 18F-FDG-PET/CT allows early non-
invasive evaluation of therapy at extrapulmonary sites and
is particularly helpful when there is multisite involvement as
is usually the case in TB.53,55,58
Prognosis and Prediction of
Outcome
The burden of infection before initiating anti-TB treatment
as assessed by 18F-FDG-PET/CT was found to predict outcome
Figure 2 Maximum intensity projection 18F-FDG-PET images in a 30-year-old woman with TB-HIV coinfection on TB therapy at baseline (A),
2 months (B), 6 months, and (D) 9 months. CD4 count was 86, and viral load was 122 copies per mL at baseline.
(A) Baseline study shows abnormal 18F-FDG accumulation in cervical, mediastinal abdominal, and pelvic nodes because of TB. There
were also lung lesions that are not demonstrated on the MIP.
(B) Disease activity in the pelvic and mesenteric nodes increased, whereas the cervical and mediastinal nodes showed decreased 18F-FDG
activity after 2 months of anti-TB treatment (differential response of lesions to therapy).
(C) Significant disease activity is still noted in the abdominal and mediastinal nodes after 6 months of TB treatment. There is complete
resolution of cervical and mediastinal nodes
(D) TB Therapy was extended for a further 3 months. At the end of 9 months of TB treatment, there is complete resolution of all the
lesions.
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of therapy. Using a cutoff SUVmax of 8.15, this prediction
could be made with a sensitivity of 88% and a specificity of
81%.57 This is a very important finding, revealing the ability
of 18F-FDG-PET/CT to provide prognosis before the start of
therapy. 18F-FDG-PET/CT, however, is expensive and cannot
be recommended in all patients with TB before therapy is
started. To make this finding relevant, another study evalu-
ated the ability of 18F-FDG-PET/CT to distinguish responders
from nonresponders by evaluating the lymph nodes of pa-
tients at 4 months into treatment. In this study, 20 patients
with HIV-TB coinfection were evaluated. Responders could
be discriminated from nonresponders with a sensitivity of 88%
and a specificity of 85% using a cutoff SUVmax of 4.5 for
lymph nodes.56 The findings from this study enable
18F-FDG-PET/CT evaluation to be limited to patients who
are already on treatment and suspected to be resistant to
their current anti-TB regimen. Figure 5 shows a patient
with high disease burden at baseline with intense uptake in
lymph node basin, that has been found to be a predictor of
poor outcome to treatment. Using the 4-month follow-up
scan without the baseline study, the intense uptake in
the lymph nodes would have identified the patient as a
nonresponder.
Heterogeneous Response of TB
Lesions to Anti-TB Medication
TB lesions are very complex and dynamic, with both spatial
and temporal heterogeneity occurring within the same patient.
TB lesions have divergent trajectories occurring indepen-
dently of other lesions in the same host. In untreated patients,
these dynamic temporal changes have been imaged with
18F-FDG-PET/CT.45 A study compared disparate imaging re-
sponse to anti-TB therapy with results from deep genome
sequencing of serial sputum culture in MDR TB. The study
demonstrated clear evidence of branched microevolution of
M tuberculosis in vivo and suggested these complex subpopu-
lations contribute to the different lesion responses.44
18F-FDG-PET/CT has the advantage of following up these
lesions with differential response over time and can detect
at an early point in time a TB lesion that may not respond.
Figure 3 Extensive pulmonary cavitation demonstrated on the MIP images that show response to anti-TB therapy after 2 months in a 21-
year-old woman with pulmonary TB.
(A) Baseline study with multiple cavities bilaterally the most intense lesions has an SUVmax of 13.5 and 10.97 in the right and left lungs,
respectively.
(B) Two-month follow-up study still has active disease in the lungs bilaterally but less extensive and much less 18F-FDG avid compared
with the baseline study SUVmax of the most intense pulmonary lesions have reduced to 9.3 and 7.91 in the right and left, respectively.
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Figures 2 and 4 demonstrate the phenomenon of differen-
tial response in TB that occur frequently in follow-up of anti-
TB treatment with 18F-FDG-PET/CT. Differential response to
anti-TB on 18F-FDG-PET/CT may be because of TB. However,
heterogeneous response may also occur when TB coexists with
another pathology, and careful evaluation of the findings and
histology may be useful in making the distinction. A similar
phenomenon has also been noted when 18F-FDG-PET/CT
Figure 4 Twenty-year-old woman with TB-HIV coinfection defaulted treatment present with smear-positive pulmonary TB.
(A) Baseline MIP, PET, CT, and fused PET/CT showing bilateral upper lobe cavitation. SUVmax of the left lung lesion is 18.34.
(B). After 2 months, marked improvement seen in pulmonary lesions with SUVmax of left lung lesion now 8.52. New cervical, axillary,
and abdominal nodes with SUVmax of 7.3 are noted. Cervical and axillary nodes are most likely reactive lymphadenopathy due to HIV
because of symmetrical pattern.
(C) Six months end of therapy scan shows marked improvement in the pulmonary and abdominal lymphadenopathy. Left lung lesion
with an SUV of 1.5; abdominal node was 3.3. Patient had been sputum negative from month 2, was gaining weight, and ESR and CRP were
decreasing. Therapy stopped, and patient showed no evidence of disease after a year of follow-up.
Figure 5 Poor response to anti-TB treatment: MIP, PET, CT, and fused images showing increasing FDG avidity over time in a 37-year-old man.
(A) Baseline study demonstrates extensive TB involving the lung parenchyma and cervical, clavicular, and mediastinal nodes. SUVmax
right cervical 9, left cervical 9.4, and mediastinal nodes 12.
(B) Follow-up study after 2 months of anti-TB shows more avid lesions, with SUVmax of the right cervical left cervical and mediastinal
nodes being 20.8, 13.9, and 18.1, respectively. More avid and larger inguinal nodes also present on the follow-up study.
173Monitoring response to therapy
is used in monitoring cancer. In 1 report, there was a
heterogeneous radiological response that was suspected to be
caused by tumor heterogeneity, but biopsy of the persistent
metabolic lesion diagnosed TB.68 Figure 6 demonstrates a case
of differential response on the follow-up study where the
18F-FDG-PET/CT findings demonstrated both progression and
regression of the different lesions present.
Monitoring Response on
Completion of TB Therapy
An international study involving 113 HIV-negative patients
was conducted with 18F-FDG-PET/CT scans done at differ-
ent time points before, during, and after anti-TB therapy.69
On completion of therapy, the study found that patients who
had achieved a clinical cure had different patterns of 18F-FDG
uptake when compared with baseline study. In some pa-
tients, there was complete resolution of metabolic activity in
lesions that were seen at baseline; in others, most of the lesions
resolved, with a few just above background or reference struc-
ture. In others, however, some lesions were more intense than
the baseline scan or new lesions appeared in patients who
achieved and sustained a clinical cure. These new TB lesions
may be because of differential response of the various TB
lesions and microevolution in subpopulations of M tubercu-
losis in patients. These bacilli may be contained by the host
or give rise to active disease. This presents a challenge in in-
terpretation of end-of-treatment 18F-FDG scans. The finding
of 18F-FDG uptake alone in the absence of clinical data to
suggest active disease after a patient has completed chemo-
therapy may not be because of active disease but may represent
the host response to replicating bacilli, which are well con-
tained by the immune system.70 18F-FDG-PET findings must
be carefully correlated with clinical data when interpreting
end-of-therapy scans. Figure 7 shows a baseline and end-of-
treatment scan in a patient with HIV-TB coinfection. There
is still uptake in the mediastinal nodes at the end of therapy.
The patient clinically was cured and was followed up for a
year, with no evidence of active TB.
Monitoring Response in Treated
Patients With Latent TB With
FDG-PET/CT
18F-FDG-PET/CT has also been evaluated for its usefulness
in monitoring therapy in patients with latent TB who re-
ceived anti-TB preventive therapy latent infection. This study
included 5 asymptomatic subjects with no radiological evi-
dence of disease who had positive QuantiFERON tests. A
decrease in metabolic activity was noted in the thoracic lymph
nodes at the end of treatment in most lesions; however, the
authors were unable to determine whether the findings were
the result of treatment or the natural history of latent TB.49
They concluded that 18F-FDG-PET/CT might be useful for
studying early events in latent TB.
Figure 6 MIP, PET, CT, and fused images in a 41-year-old woman with TB, demonstrating a heterogeneous response.
(A) Baseline study demonstrating 18F-FDG-avid cervical and mediastinal nodes. SUVmax of the intense right hilar lesion is 14.81. A pleural-
based lung lesion is noted anteriorly on the left.
(B) Follow-up scan demonstrates complete resolution of cervical, paratracheal, and subcarinal nodes with increase in size and avidity of
the right hilar lesion, with SUVmax of 16.78. The right pleural-based lesion also increased in size. Biopsy of the lung lesion noted showed
granulomatous and necrotic tissue with no evidence of malignant cells and no acid-fast bacilli present.
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Review Papers on TB and FDG
Several authors have highlighted the role of 18F-FDG in moni-
toring response to anti-TB medication in various review articles
(Table 2). Some of these reviews focus on certain special issues
such as TB in children, extrapulmonary TB, role of 18F-FDG
as a biomarker in TB, and multidrug-resistant TB.2,71-73 Other
reviews emphasize the response assessment as being the most
important role of 18F-FDG-PET/CT in TB image with the ability
to assess disease activity over time with semiquantitative
measures.14,74-79
Monitoring Therapy in Patients
With HIV-TB Coinfection
Patients with TB and HIV coinfection may present with atypi-
cal patterns of disease. The presentation of pulmonary disease
depends on the extent of immunosuppression.1,14 Patients with
suppressed viral loads and high CD4 count may present as
typical TB, but as the immunity is depressed, lung cavita-
tion occurs less frequently and TB lesions may involve lung
apices less commonly.76,77 Monitoring with 18F-FDG-PET/CT
is very useful as these patients are more frequently sputum
negative and they present with extrapulmonary disease more
often. On 18F-FDG-PET/CT, HIV-related lymphadenopathy may
show metabolic uptake that may be difficult to distinguish
from TB lymphadenitis.78 These nodes very often may not be
apparent on the baseline study but usually present on follow-
up scans (Fig. 7). HIV lymphadenopathy frequently involves
the cervical, axillary, and inguinal nodes and is frequently
bilateral.79,80 The appearance of these peripheral nodes in a
patient with HIV-TB coinfection on anti-TB being moni-
tored with 18F-FDG-PET/CT should not be mistaken for
differential response. Patients with TB-HIV may be started on
anti-TB therapy and then later started on antiretroviral therapy.
This can cause increased inflammation in existing TB lesions
because of immune reconstitution and may be misinter-
preted as poor response. A careful history, viral load CD4 count,
and time of initiation of antiretroviral therapy are necessary
Figure 7 Baseline (A) and end of TB therapy (B) maximum intensity projection images in a 27-year-old man with TB-HIV coinfection showing
good response to therapy.
(A) Baseline study shows diffuse FDG accumulation in the lung parenchyma. Widespread 18F-FDG-avid lymph nodes because of TB lymph-
adenitis demonstrated in the cervical mediastinal, abdominal, and pelvic nodes. There is also diffuse intense splenic uptake noted on the
baseline study.
(B) Following 6 months of TB treatment, there is complete resolution of the parenchymal lung lesions and marked reduction of FDG
accumulation in the lymph nodes. The spleen is still more intense than the liver but much less intense than baseline study. The symmetrical
axillary and inguinal uptake on the end of treatment study is most likely because of HIV-associated lymphadenopathy.
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to give the correct interpretation of an 18F-FDG-PET/CT used
to monitor anti-TB.
Invasive Fungal Infections
IFIs are relatively uncommonbut have aworldwide distribution,
although certain species and are endemic in certain geo-
graphical areas. IFIs have a high morbidity and mortality if
diagnosis and early initiation of appropriate therapy are delayed.
Monitoring IFI therapy is extremely important as duration of
therapy is not well established in some cases and given over
long periods. Again, antifungal agents frequently have side
effects, and resistance by fungi may develop.81 Furthermore,
IFIs frequently occur in patients with hematologic malignan-
cies, and solid tumors, and in patients who have undergone
organ transplant who are being considered for treatment or are
already on therapies that would depress their immune system.82
If IFIs are not properly treated before institution of such therapy,
the infection may disseminate, resulting in high morbidity or
even mortality in these patients.16 In some IFIs, the fungi lo-
calize to the tissue after clearing from blood such as chronic
disseminated candidiasis. In such cases, the conversion of blood
culture from positive to negative may not indicate infection
is cleared, and other biomarkers such as imaging will be im-
portant to determine the elimination of the IFI.
18F-FDG-PET or PET/CT in
Monitoring Antifungal Therapy
in IFIs
FDG-PET has been used to monitor IFI usually correlating
with clinical outcome.83 In 1 case, 18F-FDG-PET/CT was more
accurate than MRI in showing disease progression when
MRI findings remained unchanged.84 In the literature,
18F-FDG-PET/CT was useful to monitor therapy in different
sites including lungs, skeleton, central nervous system,
adrenals, and prosthetic heart valves.85-89 18F-FDG-PET/CT has
been used to determine duration of therapy led to cessation
of antifungal therapy at a time when there was no resolution
of the morphologic imaging.90,91 18F-FDG-PET/CT also detected
poor response to antifungal therapy, leading to a change of
therapy with favorable outcome after the switch.91-94 IFIs can
be caused by a wide array of fungi, and FDG-PET/CT was
useful in monitoring disease across a broad spectrum. Table 3
summarizes the relatively few studies available in literature
on monitoring response with 18F-FDG-PET or PET/CT in IFIs.
Alveolar Echinococcosis
Alveolar echinococcosis (AE) is a zoonotic parasitic infec-
tion caused by the larval stages (metacestode) of the
Echinococcus multilocularis tapeworm found in the gut of car-
nivores. AE although a parasite, behaves like a malignancy
and metastasizes or extends from the liver where infection
usually begins. Complete surgical resection of hepatic AE offers
the best prospect for cure; however, most patients have
unresectable disease by the time of diagnosis.96 Patients are
thus subjected to lengthy and sometimes life-long antimi-
crobial treatment. Benzimidazoles are the only established drugs
effective against AE. These drugs may produce significant and
sometimes severe side effects and have a very high cost in
terms of public health and the quality of life of the patient.97
Attempts to interrupt life-long therapy require an accurate
biomarker that is able to determine that there would be no
recurrence on stopping the antiparasitic agent. Morpho-
logic imaging modalities including ultrasound, CT, and MRI
have not been useful for follow-up because neither the re-
duction in size of the lesion nor the presence of calcification
is a reliable predictor of parasitic activity.98,99
18F-FDG-PET/CT has been shown to be useful in moni-
toring patients with unresectable AE. It has been proposed
as a surrogate marker for parasitic activity especially when
combined with E multilocularis-specific serological testing by
the expert consensus group for the diagnosis and manage-
ment of cystic and AE in humans.96 18F-FDG-PET/CT causes
perilesional metabolic uptake in the AE lesions. Follow-up
scans with FDG found rapid resolution of this metabolic
uptake. Relapse of infection occurred in some patients with
Table 2 Review Articles Where Monitoring ResponseWith 18F-FDG-PET/CT Highlighted
Author Journal Comment
Pelletier-Galarneau et al71 Semin Nucl Med 2017 Role of monitoring therapy in children highlighted
Gambhir et al72 Int J Infect Dis 2017 Role of monitoring therapy in EPTB underscored
Rockwood et al73 Expert Rev Respir Med 2016 Discusses 18F-FDG-PET/CT as one of the biomarkers for monitoring
TB therapy
Ankrah et al14 Clin Trans Imaging 2016 Highlights role of FDG and other PET tracer in monitoring therapy
Skoura et al74 Int J Infect Dis 2015 18F-FDG-PET/CT is the preferred modality for assessing treatment
response
Bomanji et al75 Cold Spring Harb Perspect Med Highlights the role of 18F-FDG in monitoring therapy
Vorster et al76 Curr Opin PulmMed 2014 FDGmonitoring of therapy is discussed as potentially the most
important role of 18F-FDG-PET in TB management
Sathekge et al2 Semin Nucl Med 2013 Emphasizes role in monitoring therapy especially in context of MDR
and XDR
Sathekge et al77 Nucl Med Commun 2012 The role of 18F-FDG-PET/CT and other nuclear medicine techniques in
monitoring response is discussed
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rapid metabolic resolution whose treatment was stopped based
on PET/CT findings alone.100 One study evaluated the role
of delayed imaging in the follow-up of patients with AE. The
study evaluated 120 scans performed on 70 patients. PET/
CT imaging was acquired at 3 hours after tracer injection
instead of the conventional 1 hour. In 57 scans that were con-
sidered false negative on the 1-hour scan, definite lesions were
identified in 22.8%, and in a further 10.8% such scans were
considered indeterminate. Almost all the scans that had been
reported as indeterminate on the 1-hour follow-up scan were
positive on the delayed 3-hour imaging. In another study,
the outcome of discontinuing long-term benzimidazole
therapy in patients with unresectable AE with 18F-FDG-PET/CT
and anti-EmII/3-10 was evaluated in 34 patients. None of the
11 patients who had negative 18F-FDG-PET/CT scan and
anti-EmII/3-10 and were discontinued developed recurrent
disease after they were followed up for a median of 70.5
months.101 These studies indicate that a combination of 3-hour
delayed 18F-FDG-PET/CT and AE-specific serology provide
the best in vivo biomarker for assessment of parasitic activ-
ity of AE.
Metabolic Dysfunction Associated
With Antiretroviral Therapy in HIV
Antiretroviral therapy used in HIV usually is taken for life
and given in combination, and side effect may occur. Lipo-
dystrophy, a side effect that is associated commonly
with antiretroviral drugs, has been described in up to
70% of patients.102 HIV infection itself contributes to
hypertriglyceridemia, insulin resistance, and other meta-
bolic abnormalities that are not completely reversed by
antiretroviral therapy.103 Newer antiretroviral agents appear
to have a better effect on lipid profile but are not com-
pletely devoid of these deleterious dyslipidemic effects.104 The
synergistic effect of these metabolic changes by both the in-
fection and the antiretroviral therapy may pose higher risk
Table 3 Original Articles of Monitoring Response in IFIs With 18F-FDG-PET or PET/CT
Author Journal and Year Type of IFIs Evaluated Comment
Franzius et al85 Clin Nucl Med 2001 Aspergillus sp. Resolution of metabolic activity in pulmonary
lesions on completion of therapy
Chamilos et al95 MedMycol 2008 Aspergillus and Zygomycosis
spp.
Metabolic resolution of infection when
morphologic lesions persisted was a frequent
finding
Teyton et al91 Clin Nucl Med 2009 Candida sp. Detected poor response to antifungal therapy
with resolution of IFI after therapy was
changed
Avet et al92 Eur J Nucl MedMol Imaging
2009
Candida sp. Detected poor response to antifungal therapy
with resolution of IFI after therapy was
changed
Xu et al93 Clin Nucl Med 2010 Candida sp. Detected poor response to antifungal therapy
with resolution of IFI after therapy was
changed, it also helped to determine duration
of therapy




Useful in monitoring therapy in pulmonary and
extrapulmonary sites of IFI including bones
and joints. Helped determine duration of
therapy. There was persistent metabolic
uptake of unknown significance in a case of
Aspergillus sp.
Miyazaki et al90 Ann Hematol 2011 Unidentified yeast-like fungi Demonstrated metabolic response to antifungal
when findings on morphologic imaging were
unchanged
Wallner et al89 Herz 2013 Candida sp. Demonstrated metabolic response in a
bioprosthetic aortic valve
Liu et al94 Clin Nucl Med 2013 Zygomycosis sp. Antifungal therapy was appropriately modified
as a result of serial 18F-FDG-PET/CT studies
Tsai et al83 Clin Imaging 2013 Histoplamosis sp. Clinical outcome correlated with response
demonstrated by 18F-FDG-PET/CT
Dubbioso et al87 J Neurol Sci 2013 Cryptococcus sp. Useful in monitoring intracranial IFI
Altini et al84 Clin Nucl Med 2015 Zygomycosis sp. Metabolic uptake demonstrated increase
uptake in keeping with worsening clinical
disease whenMRI did not show worsening of
the rhino-orbito-cerebral IFI
Kasaliwal et al88 Clin Nucl Med 2014 Histoplamosis sp. Metabolic disease activity in adrenal gland and
nodes correlated with clinical outcome
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of comorbidities especially in aging HIV-infected patients.103
It is important to detect these effects early and address the
problems associated with the metabolic dysfunction.
Preliminary data suggest 18F-FDG-PET/CT may be useful
to monitor lipodystrophy in patients with HIV on
antiretrovirals. In a prospective study that included a total
of 39 patients with HIV, 11 patients with lipodystrophy were
compared with 28 patients without lipodystrophy. Mean
SUVmax for the subcutaneous tissue was higher in lipodys-
trophy patients and also correlated with the duration of HIV
treatment.105 In another study, extremity subcutaneous adipose
tissue 18F-FDG uptake was increased in association with
reduced extremity fat. The study also found subcutaneous
adipose 18F-FDG uptake correlated to lipoatrophy present and
positively associated with insulin resistance in patients with
HIV with lipodystrophy.106 These studies suggest 18F-FDG may
be a useful biomarker for lipodystrophy in patients with HIV;
however, larger studies are needed to validate this.
FDG Monitoring in Other
Conditions
The role of 18F-FDG-PET in monitoring skeletal infections such
as spondylodiscitis and vascular graft infection has already
been discussed.21-24
Other PET Tracers
Preliminary data suggest a role for monitoring for other PET
tracer such as Ga68 citrate, F18 ethylcholine, and C11
methionine.107-109 In preclinical studies, 68Ga labeled with
triacetylfusarinine C and ferrioxamine E and [64Cu] DOTA
labeled Aspergillus fumigatus-specific monoclonal antibody are
Aspergillus-specific tracers that may have a role in monitor-
ing infections.110,111 In TB, a tracer trehalose, a non-mammalian
disaccharide is at the very early stage of development and has
shown promise in TB imaging.112 It has the potential of being
used in monitoring response.
SPECT Tracers
In the past, tracers such as Ga67 citrate, thallium, and Tc-
99m MIBI have been used in assessing response in fungal
infections, osteomyelitis, and even TB.113-115 New tracers that
may be specific to organisms have been evaluated in their role
for monitoring response such as Tc-99m-labeled fluconazole
or Tc-labeled chitin or chitinase.116-118 A SPECT tracer, Tc-
99m ubiquicidin, that localizes to infection and not
inflammation has been tested in humans and potentially has
a role in therapy response.119-121
Conclusion and Future
Perspectives
Molecular imaging allows in vivo, noninvasive, and quanti-
tative assessment of biologic process, marking it a useful
biomarker for infectious process over time. 18F-FDG-PET/CT
is the most commonly used PET radiotracer and is a useful
biomarker for monitoring bacterial, fungal, parasitic, and side
effects of viral treatment. 18F-FDG-PET/CT has been found
to be useful for monitoring infections that have complex and
long therapies. Monitoring infection with FDG allows early
detection of treatment failure, allowing a change of therapy.
It has been shown to provide prognostic information by pre-
therapeutic evaluation or distinguishing responders from
nonresponders. It is useful to provide a whole-body assess-
ment of infection, allowing differential response of different
lesions to be determined. Guidelines for the use of FDG in
monitoring infection are generally lacking, but evidence for
its use is mounting. Data are continuously emerging on the
role of PET in assessing response. New tracers have been tested
at preclinical and clinical level and are likely to dominate the
field of assessing response and providing individualized therapy
in the future.122 Pathogen-specific tracers for both PET and
SPECT at various stages of development would potentially
play a role beyond the current role played by the nonspe-
cific FDG tracer, including new serum biomarkers and drug
development.
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